Report Overview

The U.S. Liquid Biopsy Market was valued at USD 3.24 Billion in 2024 and reached USD 3.48 Billion in 2025. The market is projected to reach USD 11.37 Billion by 2034, expanding at a CAGR of 14.1% during the forecast period from 2026 to 2034. While The Liquid Biopsy Market was valued at USD 6.62 Billion in 2024 and reached USD 7.10 Billion in 2025. The market is projected to reach USD 23.20 Billion by 2034, expanding at a CAGR of 14.1% during the forecast period from 2026 to 2034. This represents an absolute dollar opportunity of USD 16.10 Billion over the analysis period.

Demand for the liquid biopsy market is anchored in clinical economics that tissue biopsy cannot match: serial sampling without surgical risk, turnaround in days rather than weeks, and access to inter-tumoral heterogeneity that single-site needle biopsies miss. Oncology accounts for approximately 86% of revenue in 2025, with non-oncology applications across non-invasive prenatal testing, transplant rejection monitoring, and infectious disease surveillance contributing the remainder. North America dominates revenue at 46.8% share because the United States hosts the deepest reimbursement infrastructure, with Centers for Medicare and Medicaid Services Local Coverage Determinations now extending Medicare to molecular residual disease testing in colorectal, breast, and bladder cancer.

Regulation drives the liquid biopsy market more than technology drives it. The May 1, 2026 FDA approval of Guardant360 CDx as a companion diagnostic for vepdegestrant in ER-positive, HER2-negative ESR1-mutated breast cancer marks Guardant's third ESR1 companion diagnostic clearance and demonstrates how PROTAC-class therapies are pulling liquid biopsy testing into mandatory biomarker gating. Across the Atlantic, EU In Vitro Diagnostic Regulation 2017/746 imposes a more stringent conformity-assessment regime than the predecessor IVD Directive, lengthening time-to-market for European launches and concentrating commercial activity around firms with established notified-body relationships. China's National Medical Products Administration approved its first companion diagnostic ctDNA assay in 2024, opening a registration pathway local players are now using to scale at home.

Technology direction has consolidated around three deposition routes. NGS multi-gene panel assays hold the leading technology position at approximately 67% of 2025 revenue, anchored by Roche's FoundationOne Liquid CDx 324-gene panel, Guardant360 CDx 74-gene panel, and the Roche AVENIO Tumor Tissue 335-gene panel aligned to FoundationOne CDx. Single-gene PCR microarrays retain a roughly 24% niche led by Bio-Rad and QIAGEN. The third route, ctDNA fragmentomics combined with methylation profiling, underpins Exact Sciences' Cancerguard MCED test commercialized in September 2025 and GeneCentric's GenomicsNext platform.

Forward outlook through 2034 hinges on three calibrated forces. First, multi-cancer early detection (MCED) tests scaling out of laboratory-developed test status into FDA premarket approval, led by Guardant Shield MCD (FDA Breakthrough Device Designation, June 2025) and Exact Sciences Cancerguard (Falcon registry enrolling 25,000 participants under FDA Investigational Device Exemption). Second, molecular residual disease testing becoming standard of care in stage II and III solid tumors, with Natera processing approximately 202,000 clinical Signatera tests in Q3 2025 alone. Third, payer coverage extending beyond Medicare into commercial plans, supporting a sustained 14.1% CAGR through 2034.

Market Definition & Scope

The liquid biopsy market is defined as the development, manufacture, and sale of non-invasive diagnostic tests that analyze circulating biomarkers extracted from blood, urine, saliva, or cerebrospinal fluid for cancer detection, treatment selection, recurrence monitoring, and select non-oncology indications. The market encompasses kits and consumables, instruments, software and bioinformatics, and laboratory-developed and FDA-approved test services across circulating tumor DNA, cell-free DNA, circulating tumor cells, exosomes and extracellular vesicles, and circulating cell-free RNA.

Scope coverage includes oncology applications (early detection, therapy selection, treatment monitoring, prognosis and recurrence detection) and non-oncology applications (non-invasive prenatal testing, organ transplant rejection, infectious disease surveillance). The analysis excludes traditional tissue biopsies, cytology-only testing without molecular analysis, and pre-clinical research-only assays without clinical or commercial deployment. Liquid biopsy represents approximately 4% of the broader USD 178 Billion in vitro diagnostics parent market and captures the highest-growth precision oncology tier of that market.

Key Takeaways

• Market Growth: The global liquid biopsy market grows from USD 7.10 Billion in 2025 to USD 23.20 Billion in 2034, a CAGR of 14.1%.
• Segment Dominance (Biomarker): Circulating tumor DNA and cell-free DNA hold the leading biomarker position at 47.5% revenue share in 2025, anchored by ctDNA's primacy in companion diagnostic and MRD applications.
• Segment Dominance (Application): Oncology applications account for 86.5% of liquid biopsy revenue in 2025, with therapy selection at 33.7% the largest clinical application sub-segment.
• Driver: Approximately 2.0 million new cancer cases projected in the United States in 2025 are pulling liquid biopsy adoption at a 13.8% CAGR through 2030, supported by NCCN guideline inclusion of Shield and Signatera in colorectal cancer screening.
• Restraint: Medicare reimbursement gaps for early detection tests outside FDA-approved indications constrain adoption; Cancerguard's USD 689 list price falls largely on patients until coverage expands.
• Opportunity: Multi-cancer early detection represents a USD 5.4 Billion incremental opportunity by 2034 if Shield MCD and Cancerguard secure broad Medicare coverage following Vanguard and Falcon study readouts.
• Trend: AI-enabled ctDNA fragmentomics combined with methylation profiling reached an estimated 28% of new commercial assays launched in 2025, up from 11% in 2022, displacing single-marker mutation panels.
• Regional: North America leads the liquid biopsy market with 46.8% share and USD 3.32 Billion in revenue in 2025, propelled by FDA companion diagnostic approvals and CMS reimbursement infrastructure.

Key Insights Summary

• On May 1, 2026, the FDA approved Guardant360 CDx as a companion diagnostic for vepdegestrant (Veppanu, jointly developed by Arvinas and Pfizer) in ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, marking Guardant's third ESR1 companion diagnostic clearance.
• Natera reported FY2025 total revenue of USD 2,306.1 million, a 35.9% increase over FY2024, with Q4 2025 revenue of USD 665.5 million and 2025 cash inflow of approximately USD 107.6 million.
• During Q3 2025, Guardant Health posted USD 265.2 million in revenue with Shield screening volume reaching approximately 24,000 tests in the quarter and 2025 guidance raised to USD 965-970 million.
• According to data from the Centers for Medicare and Medicaid Services, Guardant Shield received Advanced Diagnostic Laboratory Test status with Medicare pricing established at USD 1,495 per test, lifting per-test economics by approximately 67% versus the prior reimbursement.
• Exact Sciences brought Cancerguard, an MCED laboratory-developed test detecting more than 50 cancer types at USD 689 list price, to the United States on September 10, 2025 through Quest Diagnostics' approximately 7,000 patient access locations.
• The FDA awarded Breakthrough Device Designation to Guardant Shield Multi-Cancer Detection in June 2025, and the National Cancer Institute Vanguard study began enrolling participants to validate Shield MCD performance across ten cancer types at 60% overall sensitivity and 98.5% specificity.
• According to the European Investment Bank, Universal DX, a Spanish liquid biopsy startup, secured EUR 20 million in venture debt in February 2025 to scale early cancer detection assays, the largest single non-dilutive financing into a European liquid biopsy company in the trailing 12 months.

Competitive Landscape Overview

The liquid biopsy market is moderately concentrated at the top, with Natera, Guardant Health, F. Hoffmann-La Roche (through Foundation Medicine), and Illumina holding an estimated combined 38% to 42% revenue share in 2025, while the top ten players collectively control roughly 24% of cancer-diagnostics revenue based on 2023 baselines that have since tilted further toward the top four. Competition has shifted from instrument-driven sales to test-service delivery and reimbursement-driven economics, where ADLT pricing, Medicare coverage decisions, and NCCN guideline inclusion determine quarterly volume more than analytical sensitivity does. Specialist scale-ups including Exact Sciences (with the September 2025 Cancerguard MCED launch) and NeoGenomics (with the July 2025 NEO PanTracer LBx introduction) are pulling share from incumbent tissue diagnostic suppliers as oncologists transition serial monitoring to plasma. Privately held entrants Aqtual, Hedera Dx, Phase Scientific, and Universal DX are scaling adjacent biomarker categories (active chromatin cfDNA, urine ctDNA, methylation panels) that the diversified incumbents do not yet field commercially.

Competitive Landscape Matrix

Segmentation Analysis

The liquid biopsy market segments along five axes that procurement and clinical leadership use to evaluate vendors: by biomarker, by technology, by sample type, by clinical application, and by end user. Each axis maps to a different commercial decision and therefore a different competitive set, which is why integrated platforms (Natera, Guardant, Roche) outperform single-axis specialists in cross-sell economics and total contract value.

By Circulating Biomarker

Circulating tumor DNA and cell-free DNA together hold the leading biomarker position at 47.5% revenue share and approximately USD 3.37 Billion in 2025, supported by their primacy in companion diagnostic, MRD, and early detection workflows. Roche's FoundationOne Liquid CDx 324-gene panel and Guardant360 CDx 74-gene panel anchor the FDA-approved tier, while Signatera's tumor-informed ctDNA approach drives MRD growth at approximately 56% year-over-year volume in 2025. Cell-free DNA assays grew faster than the headline market by roughly 460 basis points in 2025.

Circulating tumor cells (CTCs) account for 21.6% of revenue at USD 1.53 Billion in 2025, anchored by Menarini Silicon Biosystems' CellSearch platform, the only FDA-cleared CTC system, and QCDx's CTC detection technology, which raised USD 7 million in May 2025 to support breast cancer clinical validation. CTC growth runs at approximately 11% CAGR, slower than ctDNA, because single-cell capture economics remain unfavorable below USD 1,500 per test.

Exosomes and extracellular vesicles capture 15.8% share at USD 1.12 Billion in 2025 and represent the fastest-growing biomarker class at approximately 19% CAGR through 2034. Bio-Techne's ExoDx Prostate IntelliScore secured CMS reimbursement approval in July 2024, opening commercial channels for exosome-based diagnostics. Other circulating biomarkers including cfRNA and circular RNA hold the residual 14.7% share at USD 1.04 Billion, with Aqtual's USD 31 million Series B (July 2025) and Circular Genomics' Alzheimer's Drug Discovery Foundation grant (July 2025) signaling investor appetite for next-wave biomarkers.

By Technology

Multi-gene parallel analysis using NGS leads the technology axis at 67.4% share and USD 4.79 Billion in 2025, anchored by Illumina NovaSeq, Roche AVENIO Edge, and Thermo Fisher Ion Torrent platforms. NGS held a 65% to 76% share across published 2024 baselines and continues to grow at the fastest rate among technology categories at approximately 16% CAGR. Single-gene analysis using PCR microarrays accounts for 24.3% at USD 1.73 Billion, anchored by Bio-Rad QX600 Droplet Digital PCR and QIAGEN therascreen single-gene panels for EGFR, KRAS, and BRAF. The residual category covering FISH, mass spectrometry, and emerging fragmentomics platforms holds 8.3% share at USD 0.59 Billion.

By Sample Type

Blood-based assays dominate at 71.5% revenue share and USD 5.08 Billion in 2025, since plasma collection is the most clinically standardized sample type and supports the highest-volume reimbursement codes. Urine-based liquid biopsies hold 12.8% share at USD 0.91 Billion, anchored by Bio-Techne's ExoDx Prostate IntelliScore and Phase Scientific's Phasify HPV technology, which secured USD 34 million in Series A funding in May 2025. Saliva, cerebrospinal fluid, and other sample types divide the residual 15.7% across niche applications, with CSF-based testing concentrated in central nervous system tumors and saliva-based assays in early-stage screening programs.

By Clinical Application

Therapy selection dominates clinical application revenue at 33.7% share and USD 2.39 Billion in 2025, driven by FDA companion diagnostic approvals for FoundationOne Liquid CDx, Guardant360 CDx, and Agilent Resolution ctDx FIRST. The May 1, 2026 Guardant360 CDx vepdegestrant approval extended the addressable label population by an estimated 18,000 patients per year. Treatment monitoring holds 28.4% share at USD 2.02 Billion. Prognosis and recurrence monitoring (MRD) accounts for 22.9% at USD 1.63 Billion and represents the fastest-growing clinical application at approximately 22% CAGR, anchored by Signatera, Reveal, and Pathlight MRD. Early detection and screening hold 15.0% share at USD 1.06 Billion, lifted by Shield CRC, Galleri, and Cancerguard.

By End User

Hospitals and laboratories capture 42.7% revenue share at USD 3.03 Billion in 2025, since centralized lab services consolidate sample logistics, instrumentation, and result reporting under single contract structures. Specialty reference laboratories such as Quest Diagnostics, Labcorp, and NeoGenomics hold 27.4% share at USD 1.95 Billion and serve as the distribution backbone for Cancerguard, Galleri, and Shield. Academic and research institutions account for 18.6% at USD 1.32 Billion. Pharmaceutical and biotechnology companies, which procure liquid biopsy testing for clinical trial patient stratification, hold 11.3% at USD 0.80 Billion and represent the highest-margin end-user category.

Regional Analysis

U.S. Liquid Biopsy Market Regional Overview

The United States dominates the North American liquid biopsy market and represents the largest revenue-generating country globally, driven by its advanced healthcare infrastructure, widespread adoption of precision medicine, and strong presence of leading biotechnology and diagnostics companies. The increasing prevalence of cancer, growing demand for minimally invasive diagnostic techniques, and rapid integration of next-generation sequencing (NGS) technologies into clinical practice are accelerating market growth across the country. Furthermore, favorable reimbursement policies, continuous FDA approvals for innovative liquid biopsy assays, and significant investments in oncology research are strengthening the adoption of liquid biopsy solutions across hospitals, diagnostic laboratories, and academic research institutions.

The U.S. also serves as a global innovation hub for liquid biopsy technologies, supported by extensive clinical trials, robust genomic research initiatives, and strategic collaborations between healthcare providers, pharmaceutical companies, and biotechnology firms. The expanding use of liquid biopsy for early cancer detection, companion diagnostics, treatment monitoring, and minimal residual disease (MRD) assessment, coupled with the integration of artificial intelligence and multi-omics technologies, is expected to create substantial growth opportunities. As precision oncology continues to evolve and demand for personalized cancer care increases, the U.S. liquid biopsy market is anticipated to maintain its leadership position throughout the forecast period from 2026 to 2034.

Get More Information about this report -

Request Free Sample Report

Key Market Segment

By Circulating Biomarker

• Circulating Tumor DNA (ctDNA)
• Circulating Tumor Cells (CTCs)
• Cell-Free DNA (cfDNA)
• Extracellular Vesicles (EVs) & Exosomes
• Others

By Technology

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescence In Situ Hybridization (FISH)
• Immunoassays
• Others

By Sample Type

• Blood
• Urine
• Saliva
• Cerebrospinal Fluid (CSF)
• Others

By Clinical Application

• Cancer Screening & Early Detection
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring
• Others

By End User

• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies

By Regional Coverage

• US